Secondary Prevention of VTE in Patients With Cancer and Catheter-Related Upper Extremity Deep Vein Thrombosis

Summary

This trial seeks to evaluate a management strategy after the acute treatment duration (≥ 3 months of therapeutic anticoagulation) for patients with cancer and catheter-related upper extremity deep vein thrombosis (DVT).

Eligibility

Inclusion Criteria:

1. Adult patients (≥ 18 years old) with active cancer, defined as cancer (other than localized non-melanoma skin cancer) diagnosed or treated within 6 months, or the presence of metastatic, recurrent, or progressive malignancy, ongoing anticancer therapy, or hematological malignancy not in complete remission.
2. Objectively confirmed catheter-related upper extremity DVT and treated with any standard therapeutic anticoagulation (including LMWH dose reduction to 75% after the first month) for at least 3 months.
3. Able and willing to provide informed consent.

Exclusion Criteria:

1. Active bleeding or other reasons for which anticoagulation is contraindicated.
2. Other indications requiring ongoing therapeutic dose of anticoagulation as deemed necessary by treating physicians (such as atrial fibrillation, mechanical heart valve, etc.).
3. Anticoagulation has been permanently stopped or reduced to prophylactic dose prior to enrollment for any reasons, except for participants who were transitioned to apixaban dosing regimen consistent with the protocol (2.5 mg twice daily) for ≤ 3 days .
4. Known contraindication for apixaban, such as allergy, hypersensitivity, or pregnancy.
5. Concomitant use of strong inhibitors or inducers of both cytochrome P450 3A4 (enzyme) and P-glycoprotein.

Conditions4

Interventions1

Related trials

• AntiCoagulation Versus AcetylSalicylic Acid After Transcatheter Aortic Valve Implantation — Oslo University Hospital
• Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis — Asian Institute Of Medical Sciences
• COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation — Ottawa Hospital Research Institute
• Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma — Centre Hospitalier Universitaire de Saint Etienne
• Pharmacokinetics of Apixaban in Peritoneal Dialysis — Chinese University of Hong Kong
• Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies — Medical University of Gdansk
• Anticoagulation in ICH Survivors for Stroke Prevention and Recovery — Yale University
• Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation — Regeneron Pharmaceuticals

Browse More Trials